Diffocin RBD Engineering for Selective C. difficile Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to specifically target and eliminate Clostridium difficile bacteria without harming commensal gastrointestinal bacteria, particularly in the context of increasing antibiotic resistance and the emergence of hypervirulent strains.
Innovation Solution
Isolation and genetic engineering of the diffocin gene cluster to produce R-type high molecular weight bacteriocins that can be expressed in aerobic bacteria, altering their specificity to target Clostridium difficile strains, and administering them to eliminate the pathogen from the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are administered to eliminate C. difficile, then the pathogen is killed, but commensal gastrointestinal bacteria are also harmed
Solution Approach 1:
The diffocin bacteriocin is engineered with a specific receptor binding domain that provides local specificity to C. difficile cell surface receptors, allowing selective killing of the pathogen while leaving commensal bacteria unaffected. This localized targeting capability resolves the contradiction between effective pathogen elimination and preservation of beneficial microbiota.
Solution Approach 2:
The diffocin gene cluster is segmented into functional modules including a base plate attachment region and a variable receptor binding domain. This modular structure allows independent optimization of killing efficiency and target specificity, enabling effective C. difficile elimination without affecting other bacteria.
2Reliability
If antibiotics are used to treat C. difficile infection, then bacterial load is reduced, but antibiotic resistance increases
Solution Approach 1:
The patent replaces the chemical mechanism of traditional antibiotics with a biologically-specific bacteriocin-based killing mechanism. Diffocins kill C. difficile through receptor-specific binding and membrane disruption rather than interfering with universal bacterial metabolic pathways, thereby eliminating the selection pressure that drives antibiotic resistance while maintaining effective pathogen clearance.
3Object-affected harmful factors
If R-type bacteriocins are engineered to target C. difficile, then specificity is improved, but device complexity increases
Solution Approach 1:
The diffocin gene cluster utilizes universal bacteriocin production mechanisms found in many bacteria, combined with a swapable receptor binding domain module. This allows the system to achieve high targeting specificity through modular domain exchange rather than complete redesign, reducing engineering complexity while maintaining specificity.
Data Source
AI summary
This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill Clostridium difficile bacteria, dangerous pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous aerobic producer cells. Disclosed also are small, non-ORF1374 receptor binding domains (RBDs), which are incorporated into diffocins to form engineered or variant diffocins having altered killing spectra. Variant diffocins provided herein may include a heterologous RBD and its cognate base plate attachment region (BPAR), or a fused BPAR. This invention offers a potent bactericidal agent with increased thermal and pH stability, and methods for producing it, in order to kill selectively C. difficile bacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.